News
IBIO
2.650
-0.75%
-0.020
Weekly Report: what happened at IBIO last week (1028-1101)?
Weekly Report · 1d ago
Weekly Report: what happened at IBIO last week (1021-1025)?
Weekly Report · 10/28 09:38
iBio Unveils AI-Driven Antibody Discovery Strategy
TipRanks · 10/23 13:28
Weekly Report: what happened at IBIO last week (1014-1018)?
Weekly Report · 10/21 09:38
Weekly Report: what happened at IBIO last week (1007-1011)?
Weekly Report · 10/14 09:46
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/10 15:10
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/09 15:00
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/07 16:31
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/07 12:08
Weekly Report: what happened at IBIO last week (0930-1004)?
Weekly Report · 10/07 09:43
Weekly Report: what happened at IBIO last week (0923-0927)?
Weekly Report · 09/30 09:40
Weekly Report: what happened at IBIO last week (0916-0920)?
Weekly Report · 09/23 09:40
AAR, ShiftPixy And 3 Stocks To Watch Heading Into Monday
Benzinga · 09/23 08:47
iBio GAAP EPS of -$4.03, revenue of $0.23M beats by $0.2M
Seeking Alpha · 09/20 20:19
iBio FY 2024 GAAP EPS $(6.50) Beats $(7.41) Estimate, Sales $225.000K Beat $25.000K Estimate
Benzinga · 09/20 20:09
*IBio 1Q Rev $200,000 >IBIO
Dow Jones · 09/20 20:06
Press Release: iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Dow Jones · 09/20 20:05
Press Release: iBio Reports Fiscal Year 2024 -2-
Dow Jones · 09/20 20:05
Weekly Report: what happened at IBIO last week (0909-0913)?
Weekly Report · 09/16 09:37
Weekly Report: what happened at IBIO last week (0902-0906)?
Weekly Report · 09/09 09:40
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.